# A fatty acid amide protected mouse retinas

> Erucamide activated retinal myeloid cells through TMEM19 and preserved tissue, vessels and some electrical responses in mouse models, but it has not been tested as a treatment in people.

_Source: Peer-reviewed Nature Neuroscience study; verified against the journal full text, PubMed/Europe PMC PMID 42321469 and Crossref DOI metadata · 2026-10-14 · 6 min read · Verified against primary sources_

Canonical: https://iyu.app/e/erucamide-tmem19-retinal-degeneration

## The 60-second version

Erucamide activated a TMEM19-dependent support response in retinal myeloid cells and improved several disease measures in mouse retinas.

**Key points**

- The molecule was reduced in degenerating rodent retinas and was delivered using porous silicon nanoparticles.
- Two genetic mouse models showed benefits in retinal structure, vessels and selected electrical responses.
- Binding, knockdown and blocking experiments support a pathway from erucamide through TMEM19 to growth and survival signals.
- Human evidence was limited to six donor retinas and cultured human-derived cells; there was no patient treatment trial.

**Verdict.** This is a well-supported preclinical mechanism and a drug-development lead, not an available therapy or a reason to take supplements.

## Full explainer

> **⚑ Caveat:** This is preclinical research, not a human treatment trial. The main benefits came from injections into mouse eyes; the human work consisted of six postmortem donor retinas and laboratory-grown cells.


### Bottom line — A support signal slowed retinal damage in mice

A Nature Neuroscience study found that erucamide, a 22-carbon omega-9 fatty acid amide, was depleted in degenerating rodent retinas. Delivering it with porous silicon nanoparticles preserved retinal layers and vessels and improved selected electrical responses in two mouse models of inherited retinal degeneration.

- **2** — genetic mouse models tested
- **214 ng** — erucamide dose per rd10 eye injection
- **6** — postmortem human donor retinas assayed


### What changed — The benefit covered tissue, vessels and part of the light response

- **Retinal structure:** In rd10 mice, treated eyes retained thicker outer and inner nuclear layers than vehicle-treated eyes.
- **Blood vessels:** Erucamide protected the deep retinal vascular plexus from loss.
- **Electrical function:** Selected dark-adapted B-wave responses improved, while A-wave recovery was modest and not statistically significant.
- **Second model:** Rho P23H mice also showed improvements in inner-retinal thickness, vessel density and selected electroretinography measures.


### Mechanism — TMEM19 connected the lipid signal to immune support

Erucamide accumulated in CD11b-positive retinal myeloid cells and increased growth and survival signals. Photoaffinity proteomics identified TMEM19 as a binding protein. When the researchers knocked down TMEM19 in cells or mouse eyes, much of the cytokine response and retinal rescue disappeared.

> The study does not show a fatty acid directly rebuilding the retina; it shows a candidate signal that prompts myeloid cells to support a damaged neurovascular unit.


### Human evidence — Presence and cell response are not clinical efficacy

The team detected erucamide in six postmortem human donor retinas and observed signaling changes in human induced-pluripotent-stem-cell-derived macrophage precursor cells. No person received erucamide, and the study provides no clinical dose, safety profile or evidence of restored vision in patients.


### Limits — Delivery and vascular safety remain major questions

The molecule required a specialized nanoparticle carrier and injection into the eye. The pathway increases angiogenic factors, which may support vessels in one setting but could be risky where abnormal vessel growth drives disease. The tested mice showed no aggressive choroidal neovascularization, but longer and broader safety studies are still needed.

The practical conclusion is to watch the development of erucamide analogues and TMEM19-targeted approaches, not to use fatty-acid supplements or alter eye treatment. Translation would require pharmacology, toxicology and human trials.


## Primary sources

- [Nature Neuroscience research article](https://doi.org/10.1038/s41593-026-02341-w)
- [PubMed record 42321469](https://pubmed.ncbi.nlm.nih.gov/42321469/)
- [Europe PMC full text PMC13433267](https://europepmc.org/articles/PMC13433267)
- [Crossref DOI record](https://api.crossref.org/works/10.1038/s41593-026-02341-w)
- [US National Eye Institute: retinitis pigmentosa](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/retinitis-pigmentosa)
- [Telegram source post 1552](https://t.me/CNSmydream/1552)

---
_Published by iyu (https://iyu.app) — the day's AI news, checked against primary sources and rewritten in plain language. Free to quote with attribution and a link to the canonical URL._